Dose-independent pharmacokinetics of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543, after intravenous and oral administration to rats: Hepatic and intestinal first-pass effects

Journal of Pharmaceutical Sciences

Volumn 92, Issue 1, 2003, Pages 190-201

  Lee, Mi H ^a   Bae, Soo K ^a   Kim, Eun J ^a   Kim, Yoon G ^a   Kim, Sun O ^b   Lee, Dong H ^b   Lim, Hong ^b   Yoo, Sung E ^c   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b Dongbu Hannong Chemical Co   (South Korea)

^c Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Hepatic and intestinal first pass effects; KR 31543; Linear pharmacokinetics; Rats

Indexed keywords

6 AMINO 4 [4 CHLORO (2 METHYLTETRAZOL 5 YL)METHYLPHENYLAMINO] 3,4 DIHYDRO 3 HYDROXY 2 DIMETHOXYMETHYL 2 METHYL 2H 1 BENZOPYRAN; KR 31543; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BRAIN ISCHEMIA; BRAIN PERFUSION; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG STABILITY; FIRST PASS EFFECT; GASTROINTESTINAL TRACT; HEART; HEART OUTPUT; LIVER METABOLISM; LUNG; MALE; NONHUMAN; PORTAL VEIN; RAT;

EID: 0037223682     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10289     Document Type: Article

References (26)

1. De Keyser J, Sulter G, Luiten PG. 1999. Clinical trials with neuroprotective drugs in acute ischemia stroke: Are we doing the right thing? Trends Neurosci 22:535-540.
2. Kim SH, Moon YJ, Ryu C-K, Lee MG. 2000. Pharmacokinetics, stability, and blood partition of 7-anilino-5,8-isoquinolinedione, a new isoquinolinedione derivative. Res Commun Mol Pathol Pharmacol 107:419-429.
3. Shim HJ, Lee EJ, Kim SH, Kim SH, You M, Kwon JW, Kin WB, Lee MG. 2000. Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos 21:285-291.
4. Kim SH, Kim WB, Lee MG. 1999. Pharmacokinetic changes of a new carbapenem, DA-1131, after intravenous administration to spontaneously hypertensive rats and deoxycorticosterone acetate-salt-induced hypertensive rats. Drug Metab Dispos 27:710-716.
5. Litterst CL, Mimnaugh EG, Regan RL, Gram TE. 1975. Comparison of in vitro drug metabolism by lung, liver, and kidney of several common laboratory species. Drug Metab Dispos 3:259-265.
6. Kim SH, Choi YM, Lee MG. 1993. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm 21:1-17.
7. Kim J, Kim SH, Lee MG. 1997. Liver and gastrointestinal first-pass effects of azosemide in rats. J Pharm Pharmacol 49:878-883.
8. Xu Z-X, Tang J-P, Badr M, Melethil S. 1992. Kinetics of aluminum in rats: Effect of route of administration. J Pharm Sci 81:160-163.
9. Lee MH, Kim EJ, Kim S-O, Lee DH, Lim H, Yoo S-E, Lee MG. High-performance liquid chromatographic analysis of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543, in plasma and urine. J Liq Chromatogr Rel Technol, in press.
10. Chiou WL, Nation RL, Peng GW, Huang SM. 1978. Improved micro-scale high-pressure liquid-chromatographic assay of gentamicin in plasma. Clin Chem 24:1846-1847.
11. Chiou WL. 1978. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6:539-549.
12. Kim SH, Lee MG. 2002. Pharmacokinetics of ipriflavone, an isoflavone derivative, after intravenous and oral administration to rats: Hepatic and intestinal first-pass effects. Life Sci 70:1299-1315.
13. Chen M-L, Chiou WL. 1983. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate to rabbits after intravenous administration. J Pharm Sci 11:499-513.
14. Gibaldi M, Perrier D. 1982. Pharmacokinetics, 2nd Ed. New York: Marcel Dekker.
15. Chiou WL. 1979. New calculation method for mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci 68:1067-1069.
16. Eatman FB, Colburn WA, Boxenbaum HG, Posmanter HN, Weinfeld RE, Ronfeld R, Weissman L, Moore JD, Gibaldi M, Kaplan SA. 1977. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm 5:481-494.
17. Chiou WL. 1980. New calculation method of mean total body clearance of drugs and its application to rational regimens. J Pharm Sci 69:90-91.
18. Lee H-J, Chiou WL. 1989. Erythrocytes as barriers for drug elimination in the isolated rat liver. I. Doxorubicin. Pharm Res 6:833-839.
19. Lee H-J, Chiou WL. 1989. Erythrocytes as barriers for drug elimination in the isolated rat liver. II. Propranolol. Pharm Res 6:840-843.
20. Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
21. Mitruka BM, Rawnsley HM. 1981. Clinical Biochemical and Hematological Reference Values in Normal Experimental Animals and Normal Humans, 2nd Ed. New York: Masson Publishing USA.
22. Lee MG, Chiou WL. 1983. Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623-640.
23. Kim J, Han KS, Lee JW, Lee MG. 1998. Hepatic and intestinal first-pass effects of a new hepatoprotective agent, YH439, in rats. Res Commun Mol Pathol Pharmacol 102:125-136.
24. Kim J, Kim EJ, Han KS, Chang MS, Lee MG. 1999. Gastrointestinal first-pass effect of YJA-20379-8, a new reversible proton pump inhibitor, in rats. J Pharm Pharmacol 51:1031-1036.
25. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS, Thummel KE. 1996. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24.
26. Fitzsimmons ME, Collins JM. 1997. Selective biotransformation of the human immunodeficiency virus protease inhibitor, saquinavir by human small-intestine cytochrome P4503A4: Potential contribution to high first-pass metabolism. Drug Metab Dispos 25:256-266.